Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
China has one of the most rapidly growing pharmaceutical markets in the world, as well as a vast, rapidly expanding prevalent population of Hepatitis C (HCV) patients. The key driver of the Chinese HCV market is the increase in the drug-treated population due to the introduction of novel HCV-specific therapies that will be combined in highly effective, all-oral IFN-free regimens. Combined with increasing access to medical care and a burgeoning middle class with growing economic clout, these factors promise fast growth and significant opportunity for multinational pharmaceutical companies.
Market Covered: China
Primary research: The analysis of physician insight into current and future HCV medical practice presented in this report is based on face-to-face interviews of 50 hepatologists and gastroenterologists in China.
Patient flow model: Our quantitative analysis estimates the total size of the viremic HCV population and fragments it into subpopulations based on patients’ viremic status, HCV genotype, and prior treatment history. Ten-year annual epidemiology forecasts through 2023.